On March 3rd 2015, the US patent office granted BioArctic a US patent (US 8,968,734 B2) covering therapeutic and diagnostic antibodies for Parkinson’s disease and Dementia with Lewy Bodies.
These antibodies are a novel type of antibodies binding and reducing α-synuclein protofibrils in the brain, and therefore of important therapeutic value, since α-synuclein protofibrils are believed to be central in the Parkinson disease process. The patent covers the antibody CDR regions that are important for binding α-synuclein protofibrils. With this patent and a previous patent the company has secured the IP rights for a very important therapeutic target for Parkinson’s disease. The company is now aiming at testing the safety and efficacy of a humanized version (PD0805) of this type of novel antibodies in a first-in-man clinical trial.